Pharmacokinetics, Safety, Tolerability, and Immunogenicity of a Proposed Tocilizumab Biosimilar (MSB11456) versus US-licensed Tocilizumab: Results of a Randomized, Double-blind, Parallel-group, Single-intravenous Dose Study in Healthy Adults (APTURA II)
MSB-11456;Tocilizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Pharmacokinetics, Safety, Tolerability, and Immunogenicity of a Proposed Tocilizumab Biosimilar (MSB11456) versus US-licensed Tocilizumab: Results of a Randomized, Double-blind, Parallel-group, Single-intravenous Dose Study in Healthy Adults (APTURA II) ### Output: MSB-11456;Tocilizumab